Wire · opportunities
When Early Efficacy Data Forces a Site Ramp You Weren't Budgeted For
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Early clinical efficacy data from Aprea Therapeutics' WEE1 inhibitor trial drives an unexpected need to rapidly expand clinical trial sites, exposing significant operational and budgeting challenges related to site activation costs, biomarker eligibility workflows, and high screen failure rates in oncology trials.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You are facing unbudgeted costs and delays as oncology trials with biomarker criteria push rapid site expansion. Pin down budgets explicitly covering screen failures and startup costs now or lose months in disputes and stalled enrolment.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics